Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of “Moderate Buy” from Analysts

Posted by Francis Steltz on Jun 1st, 2026

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) has received an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $28.20.

Several analysts have recently weighed in on ELAN shares. Leerink Partners boosted their price target on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Citigroup boosted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Morgan Stanley boosted their price target on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th.

Read Our Latest Research Report on ELAN

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $23.86 on Monday. Elanco Animal Health has a 12-month low of $13.09 and a 12-month high of $27.72. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The business’s 50-day moving average price is $22.96 and its two-hundred day moving average price is $23.33. The stock has a market cap of $11.92 billion, a PE ratio of -47.72, a P/E/G ratio of 2.57 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, analysts expect that Elanco Animal Health will post 1.11 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Jeffrey N. Simmons acquired 4,971 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC lifted its stake in shares of Elanco Animal Health by 5.9% in the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Elanco Animal Health by 0.6% in the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares during the period. Northwestern Mutual Investment Management Company LLC lifted its stake in shares of Elanco Animal Health by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after acquiring an additional 428 shares during the period. Meeder Advisory Services Inc. lifted its stake in shares of Elanco Animal Health by 4.8% in the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after acquiring an additional 510 shares during the period. Finally, Bessemer Group Inc. lifted its stake in shares of Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.